Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review, H2 2016: Therapeutics report Detailing 18 Companies & 28 Molecules - Research and Markets

Research and Markets
Posted on: 11 Oct 16

Research and Markets has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016" report to their offering.

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.

Metastatic Hepatocellular Carcinoma (HCC) Metastatic hepatocellular carcinoma (HCC) is a cancer that originates in liver but metastasises to lungs, lymph nodes, adrenal gland and bones, including the skull. Symptoms include abdominal pain or tenderness, especially in the upper-right part, bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection and hemochromatosis. Treatment includes surgery, chemotherapy and radiation therapy.

Metastatic Hepatocellular Carcinoma (HCC) pipeline therapeutics constitutes close to 28 molecules. Out of which approximately 26 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 12, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Metastatic Hepatocellular Carcinoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Metastatic Hepatocellular Carcinoma - Overview
  5. Pipeline Products for Metastatic Hepatocellular Carcinoma - Comparative Analysis
  6. Metastatic Hepatocellular Carcinoma - Therapeutics under Development by Companies
  7. Metastatic Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes
  8. Metastatic Hepatocellular Carcinoma Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Metastatic Hepatocellular Carcinoma - Products under Development by Companies
  13. Metastatic Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes
  14. Metastatic Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
  • Acceleron Pharma, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • HanAll Biopharma Co., Ltd.
  • Johnson & Johnson
  • Millennium Pharmaceuticals Inc
  • Mirna Therapeutics, Inc.
  • Molecular Partners AG
  • MolMed S.p.A.
  • Novartis AG
  • OncoMed Pharmaceuticals, Inc.
  • Pfizer Inc.
  • PharmAbcine, Inc.
  • Verlyx Pharma Inc.

For more information about this report visit http://www.researchandmarkets.com/research/lhg4nc/metastatic

View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005780/en/

Business Wire
www.businesswire.com

Last updated on: 11/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.